Given an abstract of a paper, generate a title for this paper such that conveys the key focus of the paper.

Abstract: Trace metal ratios in human bones were examined to determine if there were ratios that were sufficiently consistent within an individual yet varying sufficiently from the bones of another individual so that bones in a mixed grave could be reassembled. The concentrations of 21 elements sampled at 54 places on 30 human bones in each of 5 skeletons indicated that the magnesium/zinc ratio was the most reliable and that the zinc/sodium, magnesium/sodium, and chromium/sodium ratios could be used as supplements to help reassemble human bones belonging to the same individual after all standard techniques had been used.
Reassembling scattered and mixed human bones by trace element ratios.

Abstract: Methylglyoxal bis (guanylhydrazone) (MGBG) is an inhibitor of polyamine synthesis. In vitro studies demonstrate the accumulation of some tumor cells in S and G2 phases of the cell cycle. Nineteen patients with advanced head and neck cancer were entered in a Phase II trial of MGBG. MGBG, 500 mg/M2, was administered as a brief intravenous infusion weekly for 4 weeks, then every 2 weeks. Dose modifications were based on cumulative toxicity after 2 weekly treatments. All but three patients had prior exposure to chemotherapy for disease recurrence. Of 17 patients evaluable for response and toxicity, one brief partial response was observed. The most common toxicities were mild to moderate nausea, vomiting, diarrhea, and stomatitis. Myelosuppression occurred in three patients. Dose modifications were required in four patients; a maximum dose of 700 mg/M2 was tolerated. The results of four other Phase II single and combination chemotherapy trials of MGBG in head and neck cancer are reviewed. The single agent response rate in 59 patients was 22% (range, 6%-41%). The poor response rate observed in this trial was similar to that in other trials in which a heavily pretreated group of patients was evaluated. It is concluded that single agent MGBG is not a useful drug in heavily pretreated recurrent disease patients. However, because of its biochemical effects, further testing in combination with cycle specific agents and in larger numbers of patients with minimal prior treatment may be warranted.
Phase II trial of methylglyoxal bis (guanylhydrazone) (MGBG) in advanced head and neck cancer.

Abstract: The results of forty core-decompression procedures that were performed for ischemic necrosis of the femoral head in thirty-one patients over a four-year period were retrospectively reviewed to ascertain the effectiveness of the procedure. The data did not support the published rates of success of the procedure for Stage-1 and Stage-2 lesions. With a mean length of follow-up of eighteen months, 60 per cent of the hips that had a decompression prior to collapse of the femoral head demonstrated progression of the lesion and were judged to be a failure by clinical or radiographic criteria. Computerized tomographic scans and magnetic resonance imaging proved to be 100 per cent sensitive for diagnosis in preoperative testing; isotopic bone-scanning was less sensitive (80 per cent). Functional intraoperative testing by the method of Ficat did not provide added sensitivity or specificity to the results of the preoperative bone scan. A postoperative or intraoperative fracture occurred in four hips, for an incidence that exceeded any in previously published reports. We concluded that core decompression should be considered a relatively ineffective procedure with significant morbidity.
Core decompression of the femoral head for osteonecrosis.